Metabolic Dysfunction-Associated Steatohepatitis Resources Chosen by Advanced Practice Providers
  • Clinical guidelines
  • Patient support and education resources
  • Research updates
Metabolic dysfunction-associated steatohepatitis (MASH) is driven by immune-mediated hepatic inflammation, triggered in part by lipid dysregulation, especially elevated palmitic acid, which activates the sphingolipid pathway and raises sphingosine...

FDA Approves Resmetirom for MASH

Resmetirom received accelerated FDA approval in March 2024 for treating metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2-F3),...
Corrie Berk,
CURATED BY:
Corrie Berk,
DNP, MBA, APRN

Intermittent Fasting Is an Effective Way to Reverse Fatty Liver Disease

In an interview with the Fatty Liver Alliance, Dr. Jason Fung, a nephrologist, bestselling author, and co-founder of The Fasting...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Bariatric Surgery Lowers Mortality and Heart Risk in MASLD Better Than Medications

A recent multicenter study of more than 8,600 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) found that bariatric surgery...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Physician Associate and Nurse Practitioner Contributors to the Metabolic Dysfunction-Associated Steatohepatitis Center of Excellence

POCN’s Metabolic Dysfunction-Associated Steatohepatitis Center of Excellence is curated by practicing clinical physician associates and nurse practitioners who review and select resources that are the most useful to their peers. They provide their expertise by hand-picking the latest content for advanced practice providers.

Share